PARP Inhibitor

Jesus Anampa: First-in-human trial targeting metastasis doorways in breast cancer

Jesus Anampa  Breast Oncologist at Montefiore Health System, shared on X:

“Can we prevent metastasis? Our team just published results of the first-in-human trial targeting metastasis (TMEM) doorways in breast cancer.

Thanks for all the mentorship, Joseph A. Sparano.”

Phase Ib clinical and pharmacodynamic study of the TIE2 kinase inhibitor rebastinib with paclitaxel or eribulin in HER2-negative metastatic breast cancer

Authors: Jesus D. Anampa, Daniel L. Flynn, Cynthia Leary, Sun Oh, Xiaonan Xue, Maja H. Oktay, John S. Condeelis, Joseph A. Sparano

Jesus Anampa

cancer Cynthia Leary Daniel L. Flynn Jesus D. Anampa John S. Condeelis Joseph A. Sparano Maja H. Oktay OncoDaily Oncology Sun Oh Xiaonan Xue